Biopharma Solutions

From Discovery to Clinical Reality

We support world-leading key opinion leaders (KOLs) and therapeutic developers in translating complex biological signals into safe, effective therapies. We are empowering leading clinician scientists and biopharma in clinical development and trials to identify high-resolution insights that ultimately lead to new therapies and companion diagnostics (CDx).

Clinical Development and Research Applications

Oncology Innovation in MRD & CTCs

Move beyond simple detection to full molecular characterization. Characterize circulating tumor cells (CTCs) and measurable residual disease (MRD) to map clonal evolution, confirm antigen specificity, and identify drivers of resistance.

Target Identification & New Biomarker Discovery

Use whole genome for initial target identification and pivot to targeted panels or exomes for high-volume patient stratification to significantly lower sequencing costs.

Antibody Drug Conjugate (ADC) Development

Profile tumor surface proteins with high-fidelity multiomics to ensure antibody-drug conjugates reach their intended targets and to detect rare or missed subclones that drive therapeutic escape and relapse.

Solving the QNS Crisis (FNA & FFPE)

Don't let QNS (Quantity Not Sufficient) stop your research or clinical trial. We resolve the challenges of low-input DNA, fragmented DNA and RNA in archival formalin fixed paraffin embedded (FFPE)*, and fine-needle aspirates (FNA), turning minute biopsies into rich multiomic datasets.

*FFPE multiomics solutions coming in 2026. Interested in early access? Contact us.

Neurology & Neuroscience

Resolve the somatic mosaicism that drives neurodegenerative diseases at the individual cell level. With long-read single-cell sequencing, evaluate repeat expansions in neurodegenerative diseases.

Aging & Longevity Studies

Track the accumulation of genomic damage over time with high-fidelity resolution to unlock new insights into human health span.

Cell and Gene Editing

Gene editing occurs in single cells. Evaluate on- and off-target gene edits in individual cells and leverage single-cell long-read sequencing to phase complex gene edits.

AI Dataset Partnerships

Biopharma and AI/ML companies are investing heavily to create proprietary datasets; we partner with these organizations to provide the high-fidelity, complete multiomic foundation (data) they require.